A Study Designed to Evaluate Tear Production

Launched by ALCON RESEARCH · Aug 6, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new eye drop solution called AR-15512, which is designed to help people who have dry eye disease (DED) produce more tears. Dry eye disease can cause discomfort, irritation, and blurred vision, and this study aims to see if the new treatment can improve tear production quickly after use. The trial is currently looking for participants aged 65 to 74 who have been diagnosed with dry eye disease or have reported symptoms in the past year. They should also have been using or considering using artificial tears to relieve their dry eye symptoms.

If you decide to participate, you will undergo an eye examination to ensure you are in good health, and you must not have any other significant eye conditions, recent eye surgeries, or have used certain eye treatments before the study visit. Participants can expect to receive the eye drops during the trial and will be monitored for their tear production and overall eye health. If you are interested, please discuss it with your healthcare provider to see if you meet the eligibility criteria and to learn more about the study.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • Within the last 12 months, have a previous history of dry eye disease, either clinician diagnosed or patient reported.
• • Within the last 6 months, have used, or desired to use artificial tears for dry eye symptoms.
• • Have a corrected visual acuity score of 20/200 or better in both eyes.
• • Have good general and ocular health, as determined by the investigator using medical history, ophthalmic examination and history.
• • Other protocol specified inclusion criteria may apply.
• Key Exclusion Criteria:
• • Current evidence of any clinically significant ophthalmic disease other than dry eye (for example, glaucoma or macular degeneration).
• • History of ocular surgery within 1 year of the Study Visit.
• • Use of contact lenses in either eye within 7 days of the Study Visit.
• • Use of lid hygiene (all forms of lid care) or heat masks within 7 days of the Study Visit.
• • Use of any topical ocular anti-inflammatory medications, any topical ocular corticosteroid, or any non-steroidal-anti-inflammatory agents within 30 days of the Study Visit.
• • Other protocol-specified exclusion criteria may apply.